MGMT and neoplasm: Under such a therapeutic schedule, the median overall survival (OS) could reach 14.6 months.[6] The epigenetic silencing of the deoxyribose nucleic acid (DNA) repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT, which can repair the DNA damage caused by TMZ and other alkylating agents) in tumor tissues is regarded as one of the reasons for the effectiveness of TMZ.[7,8] As such, this enzyme can be used to predict the response to TMZ.